Top

25-09-2024 | Breast Cancer | Research

Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway

Authors: Kaitao Zhu, Shiwei Li, Hongru Yao, Jilong Hei, WenGuo Jiang, Tracey Martin, Shanyi Zhang

Abstract

Purpose

Breast cancer brain metastasis (BCBM) is a deadly clinical problem, and the exact underlying mechanisms remain elusive. Junctional adhesion molecule (JAM), a tight junction protein, is a key negative regulator of cancer cell invasion and metastasis.

Methods

Junction adhesion molecule 3 (JAM3) expression in breast cancer was analyzed using bioinformatics methods and confirmed by PCR, western blotting, and immunofluorescence (IF) in cell lines. The effects of exogenous expression of JAM3 using lentiviral vectors on invasion, adhesion, and apoptosis were verified using transwell assays and flow cytometry. Differentially expressed genes (DEGs) were detected by RNA sequencing and verified by q‒PCR and Western blotting. The effect of JAM3 silencing using siRNA was assessed by an adhesion assay. Kaplan‒Meier analysis was applied to calculate the impact of JAM3 expression and classic clinicopathologic characteristics on survival.

Results

Bioinformatics analysis revealed that JAM3 expression was reduced in BCBM. Exogenous expression of JAM3 minimizes the ability of breast cancer cells to invade and adhere and promotes their apoptosis. Silencing JAM3 results in morphology changes and the recovery of invasion and adhesion to ECMs, and the TGF-β/Smad signaling pathway may be involved. JAM3 predicts less metastasis and good survival in patients with BCBM. Statistical analysis of BCBM samples detected by immunohistochemistry (IHC) and the associated clinicopathological characteristics revealed that low levels of JAM3 expression and high levels of TNF-β1 are linked to the clinical progression of both primary and metastatic breast tumors. Kaplan–Meier analysis revealed that a high expression level of JAM3 was associated with longer survival.

Conclusion

JAM3 can serve as a key negative regulator of breast cancer cell invasion, apoptosis, and brain metastasis, possibly through the TGF/Smad signaling pathway. JAM3 is anticipated to be a promising biomarker for the diagnosis and prognosis of breast cancer.

Available only for authorised users

Zhao X, Powers S (2017) New views into the Genetic Landscape of metastatic breast Cancer. Cancer Cell 32:131–133. https://doi.org/10.1016/j.ccell.2017.07.011CrossRefPubMed

Pan JK, Lin CH, Kuo YL, Ger LP, Cheng HC, Yao YC, Hsiao M, Lu PJ (2021) MiR-211 determines brain metastases specificity through SOX11/NGN2 axis in triple-negative breast cancer. Oncogene 40:1737–1751. https://doi.org/10.1038/s41388-021-01654-3CrossRefPubMedPubMedCentral

Li Y, Liu C, Chen Z, Lin H, Li X (2024) Netrin-1 protects blood-brain barrier (BBB) integrity after cerebral ischemia-reperfusion by activating the Kruppel-like factor 2 (KLF2)/occludin pathway. J Biochem Mol Toxicol 38:e23623. https://doi.org/10.1002/jbt.23623CrossRefPubMed

Qi D, Lin H, Hu B, Wei Y (2023) A review on in vitro model of the blood-brain barrier (BBB) based on hCMEC/D3 cells. J Control Release 358:78–97. https://doi.org/10.1016/j.jconrel.2023.04.020CrossRefPubMed

Hosoya KI, Takashima T, Tetsuka K, Nagura T, Ohtsuki S, Takanaga H, Ueda M, Yanai N, Obinata M, Terasaki T (2000) mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J Drug Target 8:357–370. https://doi.org/10.3109/10611860008997912CrossRefPubMed

Jin J, Cui Y, Niu H, Lin Y, Wu X, Qi X, Bai K, Zhang Y, Wang Y, Bu H (2024) NSCLC extracellular vesicles containing miR-374a-5p promote leptomeningeal metastasis by influencing blood-brain barrier permeability. Mol Cancer Res. https://doi.org/10.1158/1541-7786.MCR-24-0052CrossRefPubMedPubMedCentral

Martin TA (2014) The role of tight junctions in cancer metastasis. Semin Cell Dev Biol 36:224–231. https://doi.org/10.1016/j.semcdb.2014.09.008CrossRefPubMed

Naik MU, Naik TU, Suckow AT, Duncan MK, Naik UP (2008) Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res 68:2194–2203. https://doi.org/10.1158/0008-5472.CAN-07-3057CrossRefPubMed

Tokes AM, Szasz AM, Juhasz E, Schaff Z, Harsanyi L, Molnar IA, Baranyai Z, Besznyak I Jr., Zarand A, Salamon F, Kulka J (2012) Expression of tight junction molecules in breast carcinomas analyzed by array PCR and immunohistochemistry. Pathol Oncol Res 18:593–606. https://doi.org/10.1007/s12253-011-9481-9CrossRefPubMed

10.

Woodfin A, Voisin MB, Beyrau M, Colom B, Caille D, Diapouli FM, Nash GB, Chavakis T, Albelda SM, Rainger GE, Meda P, Imhof BA, Nourshargh S (2011) The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol 12:761–769. https://doi.org/10.1038/ni.2062CrossRefPubMedPubMedCentral

11.

Lamagna C, Hodivala-Dilke KM, Imhof BA, Aurrand-Lions M (2005) Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res 65:5703–5710. https://doi.org/10.1158/0008-5472.CAN-04-4012CrossRefPubMed

12.

Nguyen NM, de Oliveira Andrade F, Jin L, Zhang X, Macon M, Cruz MI, Benitez C, Wehrenberg B, Yin C, Wang X, Xuan J, de Assis S, Hilakivi-Clarke L (2017) Maternal intake of high n-6 polyunsaturated fatty acid diet during pregnancy causes a transgenerational increase in mammary cancer risk in mice. Breast Cancer Res 19:77. https://doi.org/10.1186/s13058-017-0866-xCrossRefPubMedPubMedCentral

13.

Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, van der Zee AG, Wisman GB (2012) A four-gene methylation marker panel as a triage test in high-risk human papillomavirus positive patients. Int J Cancer 130:1861–1869. https://doi.org/10.1002/ijc.26326CrossRefPubMed

14.

Segaert P, Lopes MB, Casimiro S, Vinga S, Rousseeuw PJ (2019) Robust identification of target genes and outliers in triple-negative breast cancer data. Stat Methods Med Res 28:3042–3056. https://doi.org/10.1177/0962280218794722CrossRefPubMed

15.

Zhang SY, Li JL, Xu XK, Zheng MG, Wen CC, Li FC (2011) HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma. J Neurooncol 105:199–210. https://doi.org/10.1007/s11060-011-0584-7CrossRefPubMed

16.

Doosti Z, Ebrahimi SO, Ghahfarokhi MS, Reiisi S (2024) Synergistic effects of miR-143 with miR-99a inhibited cell proliferation and induced apoptosis in breast cancer. Biotechnol Appl Biochem. https://doi.org/10.1002/bab.2592CrossRefPubMed

17.

Wang WW, Chen B, Lei CB, Liu GX, Wang YG, Yi C, Wang YY, Zhang SY (2017) Mir-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1. Jpn J Clin Oncol 47:690–698. https://doi.org/10.1093/jjco/hyx073CrossRefPubMed

18.

Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, Lin Z, Wang Y (2018) LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via mir-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis 9:742. https://doi.org/10.1038/s41419-018-0793-5CrossRefPubMedPubMedCentral

19.

Wu Y, Liu H, Sun Z, Liu J, Li K, Fan R, Dai F, Tang H, Hou Q, Li J, Tang X (2024) The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects. Cell Death Dis 15:455. https://doi.org/10.1038/s41419-024-06855-8CrossRefPubMedPubMedCentral

20.

Surve CR, Duran CL, Ye X, Chen X, Lin Y, Harney AS, Wang Y, Sharma VP, Stanley ER, Cox D, McAuliffe JC, Entenberg D, Oktay MH, Condeelis JS (2024) Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination. bioRxiv. https://doi.org/10.1101/2024.01.08.574676CrossRefPubMedPubMedCentral

21.

Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, Deik A, Petronio L, Tang AA, Zhu C, Wang L, Rosenberg D, Mangena V, Roth J, Chung K, Jain RK, Clish CB, Vander Heiden MG, Golub TR (2020) A metastasis map of human cancer cell lines. Nature 588:331–336. https://doi.org/10.1038/s41586-020-2969-2CrossRefPubMedPubMedCentral

22.

Wu D, Deng S, Li L, Liu T, Zhang T, Li J, Yu Y, Xu Y (2021) TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastases. Cell Death Dis 12:721. https://doi.org/10.1038/s41419-021-04004-zCrossRefPubMedPubMedCentral

23.

Peng J, Chen Y, Yin A (2024) JAM3 promotes cervical cancer metastasis by activating the HIF-1alpha/VEGFA pathway. Bmc Womens Health 24:293. https://doi.org/10.1186/s12905-024-03127-7CrossRefPubMedPubMedCentral

24.

Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M (2013) Junctional adhesion molecules 2 and 3 may potentially be involved in the progression of gastric adenocarcinoma tumors. Med Oncol 30:380. https://doi.org/10.1007/s12032-012-0380-zCrossRefPubMed

25.

Mochida GH, Ganesh VS, Felie JM, Gleason D, Hill RS, Clapham KR, Rakiec D, Tan WH, Akawi N, Al-Saffar M, Partlow JN, Tinschert S, Barkovich AJ, Ali B, Al-Gazali L, Walsh CA (2010) A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts. Am J Hum Genet 87:882–889. https://doi.org/10.1016/j.ajhg.2010.10.026CrossRefPubMedPubMedCentral

26.

Zhou D, Tang W, Zhang Y, An HX (2019) JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer. Cancer Manag Res 11:2457–2470. https://doi.org/10.2147/CMAR.S189937CrossRefPubMedPubMedCentral

27.

Benedetti A, Turco C, Gallo E, Daralioti T, Sacconi A, Pulito C, Donzelli S, Tito C, Dragonetti M, Perracchio L, Blandino G, Fazi F, Fontemaggi G (2024) ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin beta3-VEGFR2 interaction. Cell Death Dis 15:113. https://doi.org/10.1038/s41419-024-06491-2CrossRefPubMedPubMedCentral

28.

Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M (2009) Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69:1469–1476. https://doi.org/10.1158/0008-5472.CAN-08-2678CrossRefPubMed

29.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527:329–335. https://doi.org/10.1038/nature15756CrossRefPubMedPubMedCentral

30.

Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, Lee DH (2022) Integrin alphavbeta3 induces HSP90 inhibitor resistance via FAK activation in KRAS-Mutant Non-small Cell Lung Cancer. Cancer Res Treat 54:767–781. https://doi.org/10.4143/crt.2021.651CrossRefPubMed

31.

Choi S, Whitman MA, Shimpi AA, Sempertegui ND, Chiou AE, Druso JE, Verma A, Lux SC, Cheng Z, Paszek M, Elemento O, Estroff LA, Fischbach C (2023) Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer. Nat Biomed Eng 7:1455–1472. https://doi.org/10.1038/s41551-023-01077-3CrossRefPubMed

32.

Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, Dominguez-Vidana R, Hartman JD, Renwick A, Scorsone K, Bernardi RJ, Skinner SO, Jain A, Orellana M, Lagisetti C, Golding I, Jung SY, Neilson JR, Zhang XH, Cooper TA, Webb TR, Neel BG, Shaw CA, Westbrook TF (2015) The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525:384–388. https://doi.org/10.1038/nature14985CrossRefPubMedPubMedCentral

33.

Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, Kempa S, Zender L, Eilers M, Murphy DJ (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483:608–612. https://doi.org/10.1038/nature10927CrossRefPubMed

34.

Zhang Y, Xia F, Liu X, Yu Z, Xie L, Liu L, Chen C, Jiang H, Hao X, He X, Zhang F, Gu H, Zhu J, Bai H, Zhang CC, Chen GQ, Zheng J (2018) JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/beta-catenin/CCND1 signaling. J Clin Invest 128:1737–1751. https://doi.org/10.1172/JCI93198CrossRefPubMedPubMedCentral

35.

Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signaling and its role in tumor pathogenesis. Acta Biochim Pol 52:329–337CrossRefPubMed

36.

Babyshkina N, Dronova T, Erdyneeva D, Gervais P, Cherdyntseva N (2021) Role of TGF-beta signaling in the mechanisms of tamoxifen resistance. Cytokine Growth Factor Rev 62:62–69. https://doi.org/10.1016/j.cytogfr.2021.09.005CrossRefPubMed

Title: Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway
Authors: Kaitao Zhu
Shiwei Li
Hongru Yao
Jilong Hei
WenGuo Jiang
Tracey Martin
Shanyi Zhang
Publication date: 25-09-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Metastasis
Published in: Journal of Neuro-Oncology
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04797-x

Advances in Alzheimer's

Alzheimer's Disease
Independent Medical Education

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Learn more

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway

Abstract

Purpose

Methods

Results

Conclusion

Advances in Alzheimer's

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Advances in Alzheimer's